The emerging role of sunitinib in the treatment of advanced epithelial thyroid cancer: Our experience and review of literature

Mini-Reviews in Medicinal Chemistry

Volumn 11, Issue 9, 2011, Pages 746-752

  Pasqualetti, G ^a   Ricci, S ^a   Dardano, A ^a   Ferdeghini, M ^b   del Tacca, M ^a   Monzani, F ^a  

^a UNIVERSITY HOSPITAL OF PISA   (Italy)

^b UNIVERSITY OF VERONA   (Italy)

Author keywords

Metastatic disease; Sunitinib; Thyroid cancer; Tyrosin kinase inhibitor

Indexed keywords

B RAF KINASE; CYTOCHROME P450 3A4; ENDOTHELIN 1; FLUORODEOXYGLUCOSE F 18; FLUOROURACIL; GEFITINIB; KETOCONAZOLE; NAVELBINE; RADIOACTIVE IODINE; RIFAMPICIN; SORAFENIB; STAT3 PROTEIN; SUNITINIB; THYROGLOBULIN;

ADVANCED CANCER; AMENORRHEA; ANEMIA; ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; BINDING SITE; BLOOD TOXICITY; BONE METASTASIS; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CARCINOGENESIS; CARDIOTOXICITY; CIRCADIAN RHYTHM; CLINICAL TRIAL (TOPIC); COMPETITIVE INHIBITION; DIARRHEA; DISEASE SEVERITY; DRUG EFFICACY; DRUG FATALITY; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG POTENTIATION; DRUG STRUCTURE; DRUG TOLERABILITY; FATIGUE; FOLLICULAR THYROID CANCER; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL TOXICITY; HAND FOOT SYNDROME; HEART FAILURE; HUMAN; HYPERTENSION; HYPOTHYROIDISM; LEUKOPENIA; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; MEDICAL LITERATURE; MEGALOCYTOSIS; METASTASIS; NEUTROPENIA; NONHUMAN; OFF LABEL DRUG USE; OVERALL SURVIVAL; PAPILLARY THYROID CANCER; PHASE 2 CLINICAL TRIAL (TOPIC); POSITRON EMISSION TOMOGRAPHY; REVIEW; SIGNAL TRANSDUCTION; SOMATIC MUTATION; THROMBOCYTOPENIA; THYROGLOBULIN BLOOD LEVEL; THYROID CANCER; THYROID CARCINOMA; THYROID MEDULLARY CARCINOMA; TUMOR LYSIS SYNDROME;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; HUMANS; INDOLES; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; PROTEIN KINASE INHIBITORS; PYRROLES; THYROID NEOPLASMS;

EID: 79960579578     PISSN: 13895575     EISSN: 18755607     Source Type: Journal    
DOI: 10.2174/138955711796355249     Document Type: Review

References (58)

1. Shaha, A.R.; Shah, J.P.; Loree, T.R. Risk group stratification and prognostic factors in papillary carcinoma of thyroid. Ann. Surg. Oncol., 1996, 3, 534-8.
2. Jonklaas, J.; Sarlis, N.J.; Litofsky, D.; Ain, K.B.; Bigos, S.T.; Brierley, J.D.; Cooper, D.S.; Haugen, B.R.; Ladenson, P.W.; Magner, J: Robbins, J.; Ross, D.S., Skarulis, M, Maxon, H.R, Sherman, S.I. Outcomes of patients with differentiated thyroid carcinoma following initial therapy. Thyroid, 2006, 16, 1229-42.
3. Sampson, E.; Brierley, J.D.; Le, L.W.; Rotstein, L.; Tsang, R.W. Clinical management and outcome of papillary and follicular (differentiated) thyroid cancer presenting with distant metastasis at diagnosis. Cancer, 2007, 110, 1451-6.
4. Shaha, A.R.; Shah, J.P.; Loree, T.R. Differentiated thyroid cancer presenting initially with distant metastasis. Am. J. Surg., 1997, 174, 474-6.
5. Durante, C.; Haddy, N.; Baudin, E.; Leboulleux, S; Hartl, D; Travagli, JP; Caillou, B; Ricard, M; Lumbroso, JD; De Vathaire, F.; Schlumberger, M. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J. Clin. Endocrinol. Metab., 2006, 91, 2892-9.
6. B.R. Management of the patient with progressive radioiodine non-responsive disease. Semin. Surg. Oncol., 1999, 16, 34-41.
7. Kerbel, R.; Folkman, J. Clinical translation of angiogenesis inhibitors. Nat. Rev. Cancer, 2002, 2, 727-39.
8. Shibuya, M. Vascular endothelial growth factor receptor-1 (VEGFR-1/Flt-1): a dual regulator for angiogenesis. Angiogenesis., 2006, 9, 225-30.
9. Klein, M.; Vignaud, J.M.; Hennequin, V.; Toussaint, B.; Bresler, L.; Plénat, F.; Leclère, J.; Duprez, A.; Weryha, G. Increased expression of the vascular endothelial growth factor is a pejorative prognosis marker in papillary thyroid carcinoma. J. Clin. Endocrinol. Metab., 2001, 86, 656-8.
10. Lennard, C.M.; Patel, A.; Wilson, J.; Reinhardt, B.; Tuman, C.; Fenton, C.; Blair, E.; Francis, G.L.; Tuttle R.M. Intensity of vascular endothelial growth factor expression is associated with increased risk of recurrence and decreased disease-free survival in papillary thyroid cancer. Surgery, 2001, 129, 552-8.
11. Mendel, D.B.; Laird, A.D.; Xin, X.; Louie, S.G.; Christensen, J.G.; Li, G.; Schreck, R.E.; Abrams, T.J.; Ngai, T.J.; Lee, L.B.; Murray, L.J.; Carver, J.; Chan, E.; Moss, K.G.; Haznedar, J.O.; Sukbuntherng, J.; Blake, R.A.; Sun, L.; Tang, C.; Miller, T.; Shirazian, S.; McMahon, G.; Cherrington, J.M. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin. Cancer. Res., 2003, 9, 327-37.
12. Chow, L.Q.; Eckhardt, S.G. Sunitinib: from rational design to clinical efficacy. J. Clin. Oncol., 2007, 25, 884-96.
13. O'Farrell, A.M.; Abrams, T.J.; Yuen, H.A.; Ngai, T.J.; Louie, S.G.; Yee, K.W.; Wong, L.M.; Hong, W.; Lee, L.B.; Town, A.; Smolich, B.D.; Manning, W.C.; Murray, L.J.; Heinrich, M.C.; Cherrington, B.M. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood, 2003, 101, 3597-605.
14. Sakamoto, K.M. Su-11248 Sugen. Curr. Opin. Investig. Drugs, 2004, 5, 1329-39.
15. Heng, D.Y; Kollmannsberger, C. Sunitinib. Recent Results Cancer Res., 2010, 184, 71-82.
16. Sharma, S.V.; Settleman, J.; Oncogene addiction: setting the stage for molecularly targeted cancer therapy. Genes Dev., 2007, 21, 3214-31.
17. Lanzi, C.; Cassinelli, G.; Nicolini, V.; Zunino, F. Targeting RET for thyroid cancer therapy. Biochem. Pharmacol., 2009, 77, 297-309.
18. Fagin, J.A. How thyroid tumors start and why it matters: kinase mutants as targets for solid cancer pharmacotherapy. J. Endocrinol., 2004, 183, 249-56.
19. Schlumberger, M.; Sherman, S.I. Clinical trials for progressive differentiated thyroid cancer: patient selection, study design, and recent advances. Thyroid, 2009, 19, 1393-400.
20. Felsher, D.W. Oncogene addiction versus oncogene amnesia: perhaps more than just a bad habit? Cancer. Res., 2008, 68, 3081-6.
21. Arighi, E., Borrello, M.G.; Sariola, H. RET tyrosine kinase signaling in development and cancer. Cytokine Growth Factor Rev., 2005, 16, 441-67.
22. Kondo, T.; Ezzat, S.; Asa, S.L. Pathogenetic mechanisms in thyroid follicular-cell neoplasia. Nat. Rev. Cancer., 2006, 6, 292-306.
23. Ciampi, R.; Giordano, T.J.; Wikenheiser-Brokamp, K.; Koenig, R.J.; Nikiforov, Y.E. HOOK3-RET: a novel type of RET/PTC rearrangement in papillary thyroid carcinoma. Endocr. Relat. Cancer., 2007, 14, 445-52.
24. Vitagliano, D.; Carlomagno, F.; Motti, M.L.; Viglietto, G.; Nikiforov, Y.E.; Nikiforova, M.N.; Hershman, J.M.; Ryan, A.J.; Fusco, A.; Melillo, R.M.; Santoro, M. Regulation of p27Kip1 protein levels contributes to mitogenic effects of the RET/PTC kinase in thyroid carcinoma cells. Cancer. Res., 2004, 64, 3823-9.
25. Melillo, R.M.; Castellone, M.D.; Guarino, V.; De Falco, V.; Cirafici, A.M.; Salvatore, G.; Caiazzo, F.; Basolo, F.; Giannini, R.;Kruhoffer, M.; Orntoft, T.; Fusco, A.; Santoro, M. The RET/PTCRAS- BRAF linear signaling cascade mediates the motile and mitogenic phenotype of thyroid cancer cells. J. Clin. Invest., 2005, 115, 1068-81.
26. Hwang, J.H.; Kim, D.W.; Suh, J.M.; Kim, H.; Song, J.H.; Hwang, E.S.; Park, K.C.; Chung H.K.; Kim, J.M.; Lee, T.H.; Yu, D.Y.; Shong, M. Activation of signal transducer and activator of transcription 3 by oncogenic RET/PTC (rearranged in transformation/papillary thyroid carcinoma) tyrosine kinase: roles in specific gene regulation and cellular transformation. Mol. Endocrinol., 2003, 17, 1155-66.
27. Kim, D.W.; Jo, Y.S.; Jung, H.S.; Chung, H.K.; Song, J.H.; Park, K.C.; Park, S.H.; Hwang J.H.; Rha, S.Y.; Kweon, G.R.; Lee, S.J.; Jo, K.W.; Shong, M. An orally administered multitarget tyrosine kinase inhibitor, SU11248, is a novel potent inhibitor of thyroid oncogenic RET/papillary thyroid cancer kinases. J. Clin. Endocrinol. Metab., 2006, 91, 4070-6.
28. Dulgeroff, A.J.; Hershman, J.M. Medical therapy for differentiated thyroid carcinoma. Endocr. Rev., 1994, 15, 500-15.
29. Xing, M. BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications. Endocr. Rev., 2007, 28, 742-62.
30. Fenton, M.S.; Marion, K.M.; Salem, A.K.; Hogen, R.; Naeim, F.; Hershman, J.M. Sunitinib inhibits MEK/ERK and SAPK/JNK pathways and increases sodium/iodide symporter expression in papillary thyroid cancer. Thyroid, 2010, 20, 965-74.
31. Carmeliet, P. Angiogenesis in life, disease and medicine. Nature. 2005, 438, 932-6.
32. Giatromanolaki, A.; Lyberakidis, G.; Lyratzopoulos, N.; Koukourakis, M.I.; Sivridis, E.; Manolas, C. Angiogenesis and angiogenic factor expression in thyroid cancer. J. BUON., 2010, 15, 357-61.
33. Sherman, S.I. Tyrosine kinase inhibitors and the thyroid. Best Pract. Res Clin. Endocrinol. Metab., 2009, 23, 713-22.
34. Lennard, C.M.; Patel, A.; Wilson, J.; Reinhardt, B.; Tuman, C.; Fenton, C.; Blair, E. Francis GL, Tuttle RM. Intensity of vascular endothelial growth factor expression is associated with increased risk of recurrence and decreased disease-free survival in papillary thyroid cancer. Surgery, 2001, 129, 552-8.
35. Klein, M.; Catargi, B. VEGF in physiological process and thyroid disease. Ann. Endocrinol., 2007, 68, 438-48.
36. Cabanillas, M.E.; Waguespack, S.G.; Bronstein, Y.; Williams, M.D.; Feng, L.; Hernandez M.; Lopez, A.; Sherman, S.I.; Busaidy, N.L. Treatment with tyrosine kinase inhibitors for patients with differentiated thyroid cancer: the M. D. Anderson experience. J. Clin. Endocrinol. Metab., 2010, 95, 2588-95.
37. Cohen, E.E.; Needles, B.M.; Cullen, K.J.; Wong, S.J.; Wade, J.L.; Ivy, S.P.; Villaflor, V.M.; Seiwert, T.Y.; Nichols, K.; Vokes, E.E. Phase 2 study of sunitinib in refractory thyroid cancer. 2008 ASCO Annual Meeting, Abstract No: 6025 Citation: J. Clin. Oncol., 26: 2008 (May 20 suppl; abstr 6025)
38. Ravaud, A.; de la Fouchardière, C.; Courbon, C.; Asselineau, J.; Klein, M.; Nicoli-Sire, P.; Bournaud, C.; Delord, J.; Weryha, G.; Catargi B. Sunitinib in patients with refractory advanced thyroid cancer: the THYSU phase II trial. J. Clin. Oncol., 26: 2008 (May 20 suppl; abstr 6058)
39. Eisenhauer, E.A.; Therasse, P.; Bogaerts, J.; Schwartz, L.H.; Sargent, D.; Ford, R.; Dancey J.; Arbuck, S.; Gwyther, S.; Mooney, M.; Rubinstein, L.; Shankar, L.; Dodd, L.; Kaplan, R.; Lacombe, D.; Verweij, J. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer, 2009, 45, 228-47.
40. Carr LL, Mankoff D, Goulart BH, Eaton KD, Capell PT, Kell EM, Bauman J, Martins RG. Phase II Study of Sunitinib in FDG-PET Positive, Differentiated Thyroid Cancer and Metastatic Medullary Carcinoma of Thyroid with Functional Imaging Correlation. Clin. Cancer Res., 2010, 16, 5260-8.
41. Houk B.E.; Bello C.L.; Poland B.; Rosen L.S.; Demetri G.D.; Motzer R.J. Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis. Cancer Chemother Pharmacol., 2010, 66, 357-71.
42. Hong, M.H.; Kim, H.S.; Kim, C.; Ahn, J.R.; Chon, H.J.; Shin, S.J.; Ahn, J.B.; Chung, H.C.; Rha, S.Y. Treatment outcomes of sunitinib treatment in advanced renal cell carcinoma patients: a single cancer center experience in Korea. Cancer Res. Treat., 2009, 41, 67-72.
43. Schwandt, A: Wood, L.S.; Rini, B.; Dreicer, R. Management of side effects associated with sunitinib therapy for patients with renal cell carcinoma. Onco Targets Ther., 2009, 2, 51-61.
44. Van Nostrand, D. The benefits and risks of I-131 therapy in patients with well-differentiated thyroid cancer. Thyroid, 2009, 19, 1381-91.
45. Gkountouvas, A.; Kostoglou-Athanassiou, I.; Veniou, E.; Repousis, P.; Ziras, N.; Kaldrimidis, P. Hematologic toxicity in patients treated with sunitinib for advanced thyroid cancer. Thyroid, 2010, 20, 597-600.
46. Torino F.; Corsello, S.M.; Longo, R.; Barnabei, A.; Gasparini, G. Hypothyroidism related to tyrosine kinase inhibitors: an emerging toxic effect of targeted therapy. Nat. Rev. Clin. Oncol., 2009, 6, 219-28.
47. Piñar D.; Boix E.; Meana J.A.; Herrero J. Sunitinib-induced thyrotoxicosis. Endocrinol Invest. 2009, 32, 941-2.
48. Abdulrahman, R.M.; Verloop, H.; Hoftijzer, H.; Verburg, E.; Hovens, G.C.; Corssmit, E.P.; Reiners, C.; Gelderblom, H.; Pereira, A.M.; Kapiteijn, E.; Romijn, J.A.; Visser, T.J.; Smit, J.W. Sorafenib-induced hypothyroidism is associated with increased type 3 deiodination. J. Clin. Endocrinol. Metab., 2010, 95, 3758-62.
49. Wong, E.; Rosen, L.S.; Mulay, M.; Vanvugt, A.; Dinolfo, M.; Tomoda, C.; Sugawara, M.; Hershman, J.M. Sunitinib induces hypothyroidism in advanced cancer patients and may inhibit thyroid peroxidase activity. Thyroid, 2007, 17, 351-5.
50. de Groot, J.W.; Zonnenberg, B.A.; Plukker, J.T.; van Der Graaf, W.T.; Links, T.P. Imatinib induces hypothyroidism in patients receiving levothyroxine. Clin. Pharmaco.l Ther., 2005, 78, 433-8.
51. Goodman, V.L.; Rock, E.P.; Dagher, R.; Ramchandani, R.P.; Abraham, S.; Gobburu, J.V.; Booth, B.P.; Verbois, S.L.; Morse, D.E.; Liang, C.Y.; Chidambaram N.; Jiang JX.; Tang, S.; Mahjoob, K.; Jstice, R.; Pazdur, R. Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma. Clin. Cancer Res., 2007, 13, 1367-73.
52. Braverman, L.E.; Utiger, R.D.The thyroid, a fundamental and clinical text, Ninth edition, Lippincott and Wilkins, Philadelphia, 2005, pp.97-109.
53. Adams, V.R.; Leggas, M. Sunitinib malate for the treatment of metastatic renal cell carcinoma and gastrointestinal stromal tumors. Clin. Ther., 2007, 29, 1338-53.
54. Chen M.H. Cardiac Dysfunction Induced by Novel Targeted Anticancer Therapy: An Emerging Issue. Current Cardiology Reports., 2009, 11, 167-174.
55. Kappers, M.H.; van Esch, J.H.; Sluiter, W.; Sleijfer, S.; Danser, A.H.;van den Meiracker, A.H. Hypertension induced by the tyrosine kinase inhibitor sunitinib is associated with increased circulating endothelin-1 levels. Hypertension, 2010, 56, 675-81.
56. Chu, T.F.; Rupnick, M.A.; Kerkela, R.; Dallabrida, S.M.; Zurakowski, D.; Nguyen, L.; Woulfe, K.; Pravda, E.; Cassiola, F.; Desai, J.; George, S.; Morgan, J.A.; Harris, D.M.; Ismail, N.S.; Chen, J.H.; Schoen, F.J.; Van den Abbeele, A.D.; Demetri, G.D.; Force, T.; Chen, M.H. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet, 2007, 370, 2011-9.
57. Telli, M.L.; Witteles, R.M.; Fisher, G.A.; Srinivas, S. Cardiotoxicity associated with the cancer therapeutic agent sunitinib malate. Ann. Oncol., 2008, 19, 1613-8.
58. Hasinoff, B.B.; Patel, D.; O'Hara, K.A. Mechanisms of myocyte cytotoxicity induced by the multiple receptor tyrosine kinase inhibitor sunitinib. Mol. Pharmacol., 2008, 74, 1722-8.